Biogen Target Price

Analysts' average 12-month price target for Biogen is $240.

Get informed when a big investor buys or sells

+ Follow

Share Price

$216.17

Average Target Price

$237.90

10.1% upside

21 analysts in the last 4 months

High: $300 | Low: $157

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-10	HSBC	$175	19% downside
2026-09-10	Stifel NicolausPaul Matteis	$242	11.9% upside
2026-09-03	Piper Sandler	$245	13.3% upside
2026-08-25	RBC Capital	$260	20.3% upside
2026-08-13	Wolfe Research	$300	38.8% upside
2026-07-30	H.C. Wainwright	$251	16.1% upside
2026-07-30	RBC Capital	$240	11% upside
2026-07-30	Morgan StanleyTerence Flynn	$231	6.9% upside
2026-07-30	Canaccord Genuity	$248	14.7% upside
2026-07-30	UBS	$240	11% upside
2026-07-29	OppenheimerJay Olson	$300	38.8% upside
2026-07-21	GuggenheimYatin Suneja	$280	29.5% upside
2026-07-13	Truist Financial	$235	8.7% upside
2026-07-13	Wedbush	$201	7% downside
2026-07-08	Morgan StanleyTerence Flynn	$222	2.7% upside
2026-07-07	RBC Capital	$242	11.9% upside
2026-07-06	HSBCMorten Herholdt	$157	27.4% downside
2026-06-18	Morgan Stanley	$224	3.6% upside
2026-06-15	Mizuho SecuritiesSalim Syed	$221	2.2% upside
2026-06-08	Needham	$255	18% upside
2026-05-27	RBC CapitalBrian Abrahams	$227	5% upside
2026-05-15	Piper Sandler	$225	4.1% upside
2026-04-30	Morgan Stanley	$206	4.7% downside
2026-04-30	Guggenheim	$260	20.3% upside
2026-04-30	Wedbush	$196	9.3% downside
2026-04-30	RBC CapitalBrian Abrahams	$222	2.7% upside
2026-04-20	Wells FargoMohit Bansal	$250	15.6% upside
2026-04-14	Piper Sandler	$214	1% downside
2026-04-10	Morgan Stanley	$200	7.5% downside
2026-02-19	BarclaysEmily Field	$185	14.4% downside
2026-02-11	Mizuho Securities	$236	9.2% upside
2026-02-10	WedbushLaura Chico	$187	13.5% downside
2026-02-09	Wolfe Research	$231	6.9% upside
2026-02-09	H.C. WainwrightAndrew Fein	$228	5.5% upside
2026-02-09	Tudor PickeringWilliam Pickering	$201	7% downside
2026-02-09	RBC Capital	$233	7.8% upside
2026-02-09	GuggenheimYatin Suneja	$246	13.8% upside
2026-02-09	Piper Sandler	$177	18.1% downside
2026-02-09	Canaccord Genuity	$230	6.4% upside
2026-02-09	Truist FinancialDanielle Brill	$193	10.7% downside
2026-02-09	Wolfe Research	$215	0.5% downside
2026-02-08	Wells Fargo	$200	7.5% downside
2026-02-08	Morgan StanleyTerence Flynn	$190	12.1% downside
2026-02-06	BMO CapitalEvan Seigerman	$196	9.3% downside
2026-02-03	Bernstein	$191	11.6% downside
2026-01-30	OppenheimerJay Olson	$225	4.1% upside
2026-01-08	Goldman SachsSalveen Richter	$225	4.1% upside
2026-01-08	Truist Financial	$190	12.1% downside
2026-01-06	UBS	$185	14.4% downside
2025-12-12	Morgan StanleyTerence Flynn	$156	27.8% downside

Biogen (BIIB) FAQ

Biogen (BIIB) currently reports a target price of $240. Use the charts on this page to explore Biogen's target price history and peer comparisons.

Analysts' average 12-month price target for Biogen is $240, about 10.1% upside from the current share price of $216.17. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $240, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biogen, and consider following BIIB for alerts when major investors trade the stock.

Biogen is classified in the Healthcare sector. On target price, it currently shows $240. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIIB with unrelated industries.